Evaluation of HOXB13 as a molecular marker of recurrent prostate cancer
- Authors:
- Tae-O Jeong
- Kyung-Jin Oh
- Nguyen Thi Xuan Nguyen
- Young-Rang Kim
- Min Soo Kim
- Sang Don Lee
- Soo Bang Ryu
- Chaeyong Jung
-
View Affiliations
Affiliations: Department of Anatomy, Chonnam National University Medical School and Research Institute of Medical Sciences, Gwangju 501-190, Republic of Korea, Department of Urology, Chonnam National University Medical School and Research Institute of Medical Sciences, Gwangju 501-190, Republic of Korea, Department of Statistics, Chonnam National University, Gwangju, Republic of Korea, Department of Urology, Pusan National University College of Medicine, Busan, Republic of Korea
- Published online on: January 30, 2012 https://doi.org/10.3892/mmr.2012.769
-
Pages:
901-904
Metrics:
Total
Views: 0 (Spandidos Publications: | PMC Statistics:
)
Metrics:
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics:
)
This article is mentioned in:
Abstract
Many patients with prostate cancer have disease recurrence following surgical removal of tumors and fail to respond to androgen ablation therapy. Despite the existence of a number of clinical/pathological factors, it is not possible to predict which patients will fall into this category. The results of our previous studies demonstrated that the HOXB13 homeodomain protein plays a key role in the development of prostate cancer and the progression of this malignancy. In addition, HOXB13 has been reported to predict estrogen-resistant breast cancer tumors. The purpose of this study was to investigate whether HOXB13 could be used as a molecular marker to predict prostate cancer recurrence. To examine the role of HOXB13 as a molecular marker with clinical/pathological data, the expression of HOXB13 was compared using immunohistochemistry in 57 organ-confined prostate cancer tumors obtained by radical prostatectomy. There was no significant correlation between the expression of HOXB13 and most clinical/pathological parameters, including tumor margin, invasion, pathological stage and risk level. The HOXB13 expression levels correlated with the Gleason score and there was a positive correlation with the pre-operative prostate specific antigen (PSA) levels. Accordingly, the tumor specimens from 4 patients who ultimately had biochemical failure (PSA >0.2 ng/ml), all showed a high expression of HOXB13, while their risk levels were either intermediate or high. This is the first study to report that HOXB13, together with other clinical/pathological factors, can be used as a molecular marker to predict the progression of prostate cancer.
View References
|
1
|
C Abate-ShenDeregulated homeobox gene
expression in cancer: cause or consequence?Nat Rev
Cancer2777785200210.1038/nrc90712360280
|
|
2
|
R Bhatia-GaurAA DonjacourPJ
SciavolinoRoles for Nkx3.1 in prostate development and cancerGenes
Dev13966977199910.1101/gad.13.8.966
|
|
3
|
C BowenL BubendorfHJ VoellerLoss of NKX3.1
expression in human prostate cancers correlates with tumor
progressionCancer Res6061116115200011085535
|
|
4
|
MJ KimR Bhatia-GaurWA
Banach-PetroskyNkx3.1 mutant mice recapitulate early stages of
prostate carcinogenesisCancer Res6229993004200212036903
|
|
5
|
A FeberJ ClarkG GoodwinAmplification and
overexpression of E2F3 in human bladder
cancerOncogene2316271630200410.1038/sj.onc.120727414716298
|
|
6
|
L HoodJR HeathME PhelpsB LinSystems
biology and new technologies enable predictive and preventative
medicineScience306640643200410.1126/science.110463515499008
|
|
7
|
T SreenathA OroszK FujitaCJ
BieberichAndrogen-independent expression of hoxb-13 in the mouse
prostateProstate41203207199910.1002/(SICI)1097-0045(19991101)41:3%3C203::AID-PROS8%3E3.0.CO;2-J10517879
|
|
8
|
Y TakahashiJ HamadaK MurakawaExpression
profiles of 39 HOX genes in normal human adult organs and
anaplastic thyroid cancer cell lines by quantitative real-time
RT-PCR systemExp Cell
Res293144153200410.1016/j.yexcr.2003.09.02414729064
|
|
9
|
KD EconomidesMR CapecchiHoxb13 is required
for normal differentiation and secretory function of the ventral
prostateDevelopment13020612069200310.1242/dev.0043212668621
|
|
10
|
C JungRS KimHJ ZhangSJ LeeMH JengHOXB13
induces growth suppression of prostate cancer cells as a repressor
of hormone-activated androgen receptor signalingCancer
Res6491859192200410.1158/0008-5472.CAN-04-133015604291
|
|
11
|
YR KimKJ OhRY ParkHOXB13 promotes androgen
independent growth of LNCaP prostate cancer cells by the activation
of E2F signalingMol
Cancer9124201010.1186/1476-4598-9-12420504375
|
|
12
|
XJ MaZ WangPD RyanA two-gene expression
ratio predicts clinical outcome in breast cancer patients treated
with tamoxifenCancer Cell5607616200410.1016/j.ccr.2004.05.015
|
|
13
|
LG KomuvesXK MaE StelnickiS RozenfeldY
OdaC LargmanHOXB13 homeodomain protein is cytoplasmic throughout
fetal skin developmentDev
Dyn227192202200310.1002/dvdy.1029012761847
|
|
14
|
SM DhanasekaranTR BarretteD
GhoshDelineation of prognostic biomarkers in prostate
cancerNature412822826200110.1038/3509058511518967
|
|
15
|
DR RhodesMG SandaAP OtteAM ChinnaiyanMA
RubinMultiplex biomarker approach for determining risk of
prostate-specific antigen-defined recurrence of prostate cancerJ
Natl Cancer Inst95661668200310.1093/jnci/95.9.66112734317
|
|
16
|
MA RubinM ZhouSM
Dhanasekaranalpha-Methylacyl coenzyme A racemase as a tissue
biomarker for prostate
cancerJAMA28716621670200210.1001/jama.287.13.166211926890
|
|
17
|
CS FosterA FalconerAR DodsonTranscription
factor E2F3 overexpressed in prostate cancer independently predicts
clinical
outcomeOncogene2358715879200410.1038/sj.onc.120780015184867
|
|
18
|
AW PartinMW KattanEN SubongCombination of
prostate-specific antigen, clinical stage, and Gleason score to
predict pathological stage of localized prostate cancer. A
multi-institutional
updateJAMA27714451451199710.1001/jama.1997.03540420041027
|
|
19
|
Y ZhaoT YamashitaM IshikawaRegulation of
tumor invasion by HOXB13 gene overexpressed in human endometrial
cancerOncol Rep13721726200515756448
|
|
20
|
S EdwardsC CampbellP FlohrExpression
analysis onto microarrays of randomly selected cDNA clones
highlights HOXB13 as a marker of human prostate cancerBr J
Cancer92376381200510.1038/sj.bjc.660226115583692
|
|
21
|
JF ReidL LusaL De CeccoLimits of
predictive models using microarray data for breast cancer clinical
treatment outcomeJ Natl Cancer
Inst97927930200510.1093/jnci/dji153
|
|
22
|
H OkudaM ToyotaW IshidaEpigenetic
inactivation of the candidate tumor suppressor gene HOXB13 in human
renal cell
carcinomaOncogene2517331742200610.1038/sj.onc.120920016278676
|
|
23
|
KD EconomidesL ZeltserMR CapecchiHoxb13
mutations cause overgrowth of caudal spinal cordand tail
vertebraeDev
Biol256317330200310.1016/S0012-1606(02)00137-912679105
|
